Amgen, Inc. (AMGN) Holdings Boosted by Dubuque Bank & Trust Co.

Dubuque Bank & Trust Co. grew its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 2.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 90,927 shares of the medical research company’s stock after buying an additional 2,355 shares during the period. Amgen makes up 2.4% of Dubuque Bank & Trust Co.’s portfolio, making the stock its 7th biggest position. Dubuque Bank & Trust Co.’s holdings in Amgen were worth $15,812,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of AMGN. Kayne Anderson Rudnick Investment Management LLC raised its position in shares of Amgen by 6.6% during the second quarter. Kayne Anderson Rudnick Investment Management LLC now owns 33,152 shares of the medical research company’s stock worth $5,710,000 after purchasing an additional 2,044 shares during the period. Boyer & Corporon Wealth Management LLC raised its position in shares of Amgen by 11.2% during the second quarter. Boyer & Corporon Wealth Management LLC now owns 2,070 shares of the medical research company’s stock worth $357,000 after purchasing an additional 209 shares during the period. Fragasso Group Inc. raised its position in shares of Amgen by 0.7% during the second quarter. Fragasso Group Inc. now owns 20,793 shares of the medical research company’s stock worth $3,581,000 after purchasing an additional 139 shares during the period. Sterling Investment Advisors Ltd. raised its position in shares of Amgen by 1.7% during the second quarter. Sterling Investment Advisors Ltd. now owns 12,749 shares of the medical research company’s stock worth $2,196,000 after purchasing an additional 215 shares during the period. Finally, Calamos Wealth Management LLC raised its position in shares of Amgen by 583.9% during the second quarter. Calamos Wealth Management LLC now owns 9,411 shares of the medical research company’s stock worth $1,621,000 after purchasing an additional 8,035 shares during the period. Hedge funds and other institutional investors own 79.50% of the company’s stock.

AMGN stock opened at $169.43 on Friday. The firm has a market capitalization of $126,876.59, a P/E ratio of 14.00, a price-to-earnings-growth ratio of 2.16 and a beta of 1.37. Amgen, Inc. has a 1 year low of $152.16 and a 1 year high of $201.23. The company has a debt-to-equity ratio of 1.35, a quick ratio of 5.17 and a current ratio of 5.49.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Thursday, February 1st. The medical research company reported $2.89 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $3.03 by ($0.14). The company had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.84 billion. Amgen had a return on equity of 30.87% and a net margin of 8.66%. The firm’s revenue for the quarter was down 2.7% compared to the same quarter last year. During the same period last year, the firm earned $2.89 EPS. sell-side analysts forecast that Amgen, Inc. will post 13.25 earnings per share for the current fiscal year.

Amgen declared that its Board of Directors has approved a stock buyback program on Thursday, February 1st that allows the company to buyback $10.00 billion in shares. This buyback authorization allows the medical research company to repurchase shares of its stock through open market purchases. Stock buyback programs are often a sign that the company’s management believes its stock is undervalued.

The business also recently declared a quarterly dividend, which will be paid on Friday, June 8th. Shareholders of record on Thursday, May 17th will be given a dividend of $1.32 per share. This represents a $5.28 annualized dividend and a dividend yield of 3.12%. The ex-dividend date is Wednesday, May 16th. Amgen’s dividend payout ratio (DPR) is 205.45%.

In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the business’s stock in a transaction that occurred on Friday, March 16th. The stock was sold at an average price of $189.75, for a total transaction of $289,368.75. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders have sold a total of 4,575 shares of company stock worth $838,064 in the last ninety days. Insiders own 0.19% of the company’s stock.

A number of brokerages recently issued reports on AMGN. BidaskClub lowered Amgen from a “hold” rating to a “sell” rating in a research report on Saturday. Vetr lowered Amgen from a “hold” rating to a “sell” rating and set a $181.60 target price on the stock. in a research report on Tuesday, March 6th. Mizuho lifted their target price on Amgen from $192.00 to $200.00 and gave the company a “buy” rating in a research report on Monday, February 12th. Atlantic Securities lowered Amgen from an “overweight” rating to a “neutral” rating and set a $187.01 target price on the stock. in a research report on Monday, February 5th. Finally, JPMorgan Chase & Co. reissued a “hold” rating and issued a $191.00 target price on shares of Amgen in a research report on Sunday, February 4th. Two investment analysts have rated the stock with a sell rating, fourteen have issued a hold rating and eleven have given a buy rating to the company. The company has an average rating of “Hold” and an average price target of $191.26.

WARNING: “Amgen, Inc. (AMGN) Holdings Boosted by Dubuque Bank & Trust Co.” was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://www.tickerreport.com/banking-finance/3295305/amgen-inc-amgn-holdings-boosted-by-dubuque-bank-trust-co.html.

Amgen Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Heidrick & Struggles  Expected to Post Q2 2018 Earnings of $0.43 Per Share
Heidrick & Struggles Expected to Post Q2 2018 Earnings of $0.43 Per Share
TheStreet Lowers Acxiom  to C+
TheStreet Lowers Acxiom to C+
TheStreet Downgrades Gridsum  to D
TheStreet Downgrades Gridsum to D
Stifel Nicolaus Cuts Williams Pipeline Partners  Price Target to $41.00
Stifel Nicolaus Cuts Williams Pipeline Partners Price Target to $41.00
Cowen Initiates Coverage on Unum Therapeutics
Cowen Initiates Coverage on Unum Therapeutics
OneSmart International Education Group  Earns Overweight Rating from Analysts at Morgan Stanley
OneSmart International Education Group Earns Overweight Rating from Analysts at Morgan Stanley


© 2006-2018 Ticker Report. Google+.